Ranolazine 500 MG + Ranolazine 1000 MG
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout Ranolazine 500 MG + Ranolazine 1000 MG
Ranolazine 500 MG + Ranolazine 1000 MG is a phase 2 stage product being developed by Gilead Sciences for ALS. The current trial status is completed. This product is registered under clinical trial identifier NCT03472950. Target conditions include ALS.
What happened to similar drugs?
4 of 12 similar drugs in ALS were approved
Approved (4) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03472950 | Phase 2 | Completed |
Competing Products
20 competing products in ALS